2020 AACC Annual Scientific Meeting Press Program

Leveraging task targeted automation to ease the burden of COVID-19 testing

Leveraging task targeted automation to ease the burden of COVID-19 testing

The challenges that COVID-19 testing has placed on laboratories from the increased testing volumes is evident. There is also the added time pressure of releasing results promptly so those patients identified with COVID-19 can receive timely treatment. However, it is the resultant impact on the well-being of lab workers that is not often considered. They are required to work extended hours to cope with the increased workload along with the added stress of being exposed to samples potentially containing the virus.

Today, labs processing high volumes of samples can benefit from total lab automation (TLA). However, TLA systems are out of reach for labs processing less than 4,000 tubes per day. These labs can now leverage the benefits of lab automation through the adoption of task targeted automation (TTA).

Aim Lab Automation Technologies pre-analytical and post analytical COVID-19 PathFinder benchtop automation solutions can help overcome many of these COVID-19 related challenges and reduce the risk of biohazards exposure to staff.

The pre-analytical phase in managing incoming samples can often be resource-intensive and prone to errors. The PathFinder 350D Decapper Sorter is used to automatically decap and sort incoming COVID-19 VTM sample swab tubes into various destination racks ready for testing. This reduces errors from manually handled which increases productivity and safety of lab staff.

Post-analytical processing and sorting of COVID-19 samples can be achieved through Aim Lab’s compact PathFinder 350A Archiver. Sampled tubes are capped with a laminated foil seal which prevents leakage during transportation or freezer storage. When archiving tubes, the PathFinder 350A records the date and time placed along with the rack id and well location so that tubes can easily retrieved for repeat testing.

Aim Lab Automation Technologies pre- and post-analytical COVID-19 automation solutions are a cost effective, flexible, compact automation solution even under the most stressful circumstances.

Find out more

Visit aimlab.com/covid19-automation-solutions/ to find out more. 

About Aim Lab Automation Technologies

Aim Lab Automation Technologies (Aim Lab) is a designer and manufacturer of specialist laboratory automation robotics to assist in managing large numbers of samples prior to analysis in industrial and pathology laboratories.  Founded in 1975, Aim Lab has designed, manufactured and distributed over 15,000 automation systems through various analyzer manufacturers around the world.

In 2016, Aim Lab was awarded both the Australian and Queensland Export Awards for manufacturing. With a keen appreciation of customer requirements, Aim Lab is an internationally recognised innovator in the field of laboratory automation. Our products provide hands-free sample preparation, automated delivery and sample tracking through the laboratory process. With an emphasis on efficient throughput, Aim Lab systems have found success as laboratories look for cost-effective ways of processing an ever-increasing number of samples.



Filters close

Showing results

110 of 5849
Newswise:Video Embedded newswise-expert-panels-on-covid-19-pandemic-notable-excerpts-quotes-and-videos-available
VIDEO
Released: 18-Jun-2021 2:10 PM EDT
Newswise Expert Panels on COVID-19 Pandemic: Notable excerpts, quotes and videos available
Newswise

Newswise is hosting a series of Expert Panels discussion on unique aspects of the COVID-19 pandemic. This tip sheet includes some notable quotes from the panelists.

access_time Embargo lifts in 2 days
Embargo will expire: 23-Jun-2021 8:00 AM EDT Released to reporters: 18-Jun-2021 11:00 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 23-Jun-2021 8:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded virtual-event-for-june-17-11am-edt-covid-19-vaccines-and-male-fertility
VIDEO
Released: 18-Jun-2021 8:55 AM EDT
VIDEO AND TRANSCRIPT AVAILABLE: Vaccines and Male Fertility Event for June 17, 2021
Newswise

This upcoming JAMA-published study examined whether the COVID-19 vaccine impacts male fertility.

access_time Embargo lifts in 2 days
Embargo will expire: 22-Jun-2021 11:00 AM EDT Released to reporters: 18-Jun-2021 8:30 AM EDT

A reporter's PressPass is required to access this story until the embargo expires on 22-Jun-2021 11:00 AM EDT The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Released: 18-Jun-2021 7:05 AM EDT
Teamwork saves lives: COVID-19 hospital network shares key findings to improve care
Michigan Medicine - University of Michigan

Data sharing among 40 Michigan hospitals about the care and outcomes for thousands of inpatients with COVID-19 has led to reduced variation and findings that could inform care anywhere, including approaches for preventing blood clots and reducing overuse of antibiotics, as well as a risk prediction tool.

Released: 18-Jun-2021 7:05 AM EDT
One-third of older Americans delayed health care over COVID concerns
Michigan Medicine - University of Michigan

Nearly one in three Americans between the ages of 50 and 80 put off an in-person appointment for medical care in 2020 because they were worried about exposure to the novel coronavirus, new national poll data show.

Released: 17-Jun-2021 4:15 PM EDT
UNC Researchers Lead Study of Diabetes Treatment of COVID-19 Patients
University of North Carolina School of Medicine

Diabetes is one of the comorbidities most strongly associated with severe COVID-19 in the US, and data from early in the pandemic suggested individuals with type 2 diabetes faced twice the risk of death from COVID-19 and a greater risk of requiring hospitalization and intensive care. A new study shows best treatment options.

Released: 17-Jun-2021 4:10 PM EDT
Vaccination, Previous Infection, Protect Against COVID-19 gamma/P.1 Variant in Animal Model
University of Wisconsin-Madison

In a new study using variant virus recovered from one of the original travelers, researchers in the U.S. and Japan have found that vaccination with an mRNA vaccine induces antibody responses that would protect humans from infection with the gamma/P.1 variant.

Released: 17-Jun-2021 1:30 PM EDT
Hackensack Meridian Doctors, Student Help Establish Way to Prioritize Surgeries During COVID-19 lockdown
Hackensack Meridian Health

The MeNTS method of prioritizing surgeries during the height of pandemic, developed by University of Chicago, helped procedures continue during time of need

Released: 17-Jun-2021 12:55 PM EDT
‘Nanodecoy’ Therapy Binds and Neutralizes SARS-CoV-2 Virus
North Carolina State University

Nanodecoys made from human lung spheroid cells (LSCs) can bind to and neutralize SARS-CoV-2, promoting viral clearance and reducing lung injury in a macaque model of COVID-19.


Showing results

110 of 5849

close
1.44306